Why the study?
Dilated and hypertrophic cardiomyopathies have a genetic origin in 30 to 50% of cases, making evaluation of these etiologies a crucial tool in patient management.
Recognizing the main mutations associated with cardiomyopathies enables a more individualized medicine approach with early interventions, risk stratification, and family screening.
Answers are grounded in this paper and cite their sources.
Genetic evaluation aids cardiomyopathy management; leaves open precise mutation-phenotype links for targeted therapies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Hama et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: